Results 121 to 130 of about 8,505 (243)
BMJ OpenObjective To capture UK medical students’ self-reported knowledge and harm assessment of psychedelics and to explore the factors associated with support for changing the legal status of psychedelics to facilitate further clinical research.Design Cross ...
Marco Schlosser +5 more
doaj +1 more source
Objective: Despite rapid advances in psychedelic sciences and the increasing number of countries legalizing psychedelics for the treatment of mental illnesses, the attitudes, knowledge and readiness of both mental health consumers and the general ...
Nadeem, Zohaib +3 more
core +1 more source
Neuropsychopharmacology of hallucinogenic and non‐hallucinogenic 5‐HT2A receptor agonists
British Journal of Pharmacology, Volume 183, Issue 14, Page 3935-3949, July 2026.Psychedelic drugs such as LSD and psilocin were once relegated to the fringes of medical research because of their association with counterculture movements and a perceived concern about harm through recreational use, and their consequent legal prohibition in the early 1970s.
Trevor Sharp, Aurelija Ippolito
wiley +1 more source
Psychedelics, entactogens and psychoplastogens for depression and related disorders
British Journal of Pharmacology, Volume 183, Issue 14, Page 3897-3919, July 2026.Currently, the most actively investigated rapidly acting antidepressants, anxiolytics and/or anti PTSD agents, include psychedelics e.g. psilocybin, LSD, N,N‐dimethyltryptamine, ayahuasca; non‐hallucinogenic entactogens, e.g. MDMA; psychoplastogens which rapidly promote neuroplasticity, e.g.
Daniel Hoyer
wiley +1 more source
PLOS Mental HealthPsychedelics such as psilocybin, LSD, and MDMA have shown promise in treating mental health conditions (e.g., depression, post-traumatic stress disorder) among neurotypical individuals, i.e., typically developing individuals without a diagnosed ...
Sahba Afsharnia +5 more
doaj +1 more source
Psychedelics in Mental Health Treatment: Emerging Therapies and Psilocybin's Impact on Depression
openDespite the growing number of psychological disorders diagnosed over the past decades—particularly the global rise in cases of depression—progress in effective pharmacological treatments remains limited.
KNUDSEN, LILAS
core
British Journal of Pharmacology, Volume 183, Issue 14, Page 4058-4071, July 2026.Background and Purpose Serotonergic psychedelic drugs are under investigation as therapies for various psychiatric disorders, including major depression. Although serotonergic psychedelic drugs are 5‐HT2A receptor agonists, some such agonists are not psychedelic, potentially due to differences in 5‐HT2A receptor ligand bias or signalling efficacy. Here,
Aurelija Ippolito +6 more
wiley +1 more source
Psychedelics and autobiographical memory – Six open questions
Rationale Since the earliest LSD research, psychedelics have been claimed to enhance autobiographical memory. Revisiting and processing autobiographical memories has further been suggested to be a major component of the therapeutic action of ...
Samuli Kangaslampi, Morten P. Lietz
core +2 more sources
Attitudes of European psychiatrists on psychedelics: a qualitative study
Frontiers in PsychiatryIntroduction and aimIt is important to understand how mental health practitioners view recent findings on psychedelic-assisted psychotherapy (PAP) as there is potential this treatment may be incorporated into clinical practice.
Marija Franka Žuljević +3 more
doaj +1 more source